Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Bio-Techne Corporation

A Comparative Analysis of SG&A Expenses: Merck & Co., Inc. vs. Bio-Techne Corporation

In the ever-evolving landscape of the pharmaceutical and biotechnology industries, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Merck & Co., Inc. and Bio-Techne Corporation, from 2014 to 2023.

Key Insights

Merck & Co., Inc., a stalwart in the pharmaceutical sector, consistently reported SG&A expenses exceeding $10 billion annually, peaking in 2014. Despite fluctuations, Merck's expenses remained relatively stable, reflecting its robust operational strategies.

Conversely, Bio-Techne Corporation, a leader in biotechnology, exhibited a remarkable upward trend. Starting at approximately $60 million in 2014, Bio-Techne's SG&A expenses surged by over 550% to nearly $400 million by 2023. This growth underscores Bio-Techne's aggressive expansion and investment in administrative capabilities.

Conclusion

While Merck's expenses highlight its established market presence, Bio-Techne's rapid increase signals its dynamic growth trajectory. This comparison offers a window into the strategic priorities of these two influential companies.